FY2026 EPS Estimates for NAMS Lowered by Cantor Fitzgerald

Key Points

• Analysts at Cantor Fitzgerald have lowered their FY2026 earnings per share (EPS) estimate for NewAmsterdam Pharma to ($2.40), down from a previous estimate of ($2.25), while maintaining an "Overweight" rating with a target price of $42.00.
• NewAmsterdam Pharma reported a quarterly EPS of (0.15), exceeding the consensus estimate of (0.52), with revenue significantly surpassing expectations at $19.15 million compared to an estimate of $1.44 million.
• Insider trading activity includes COO Douglas F. Kling selling 100,000 shares and Director James N. Topper purchasing 8,584 shares, reflecting mixed sentiments among company insiders regarding the stock's performance.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2026 earnings estimates for shares of NewAmsterdam Pharma in a note issued to investors on Thursday, August 7th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will post earnings per share of ($2.40) for the year, down from their previous forecast of ($2.25). Cantor Fitzgerald currently has a "Overweight" rating and a $42.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.37. The firm had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%.

NAMS has been the topic of a number of other reports. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. The Goldman Sachs Group began coverage on shares of NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price target on the stock. Royal Bank Of Canada lifted their price target on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Stifel Nicolaus began coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price target on the stock. Finally, Citigroup began coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.20.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock traded down $0.65 on Monday, hitting $25.11. 521,945 shares of the stock traded hands, compared to its average volume of 877,616. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -15.50 and a beta of -0.02. The firm has a 50 day simple moving average of $21.09 and a two-hundred day simple moving average of $20.06. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $27.29.

Institutional Trading of NewAmsterdam Pharma

A number of large investors have recently modified their holdings of the company. Quarry LP purchased a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $50,000. National Bank of Canada FI acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. grew its position in NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company's stock valued at $79,000 after buying an additional 662 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after purchasing an additional 3,390 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper purchased 8,584 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was purchased at an average cost of $19.50 per share, with a total value of $167,388.00. Following the purchase, the director owned 3,022,153 shares in the company, valued at approximately $58,931,983.50. This trade represents a 0.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Douglas F. Kling sold 100,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $19.29, for a total value of $1,929,000.00. Following the completion of the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at $848,760. The trade was a 69.44% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 12,835 shares of company stock valued at $248,134 and have sold 198,612 shares valued at $4,025,887. 20.84% of the stock is currently owned by insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.